MedTrace Logo

Phase II Clinical Trial of Vitamin D3 for Reducing Recurrence of Recurrent Lower Urinary Tract Infections

NCT04859621 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2024-02-02

No results posted yet for this study

Summary

The aim of this study was to initially evaluate the optimal dose, efficacy, and safety of vitamin D3 for reducing recurrence of recurrent urinary tract infections (rUTIs).

Conditions

  • Recurrent Urinary Tract Infection

Interventions

DRUG

Vitamin D3 4000 IU

Oral administration, 2 tablet per time, qd, oral administration with the first meal, continuous use for 48 weeks

DRUG

Vitamin D3 2000 IU

Oral administration, 1 tablet of each per time, qd, oral administration with the first meal, continuous use for 48 weeks

DRUG

Placebo

Oral administration, 2 tablet per time, qd, oral administration with the first meal, continuous use for 48 weeks

OTHER

standard antibiotic therapy

standard antibiotic therapy

Sponsors & Collaborators

  • Zensun Sci. & Tech. Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Xian He, MD · Zhejiang Provincial People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-08
Primary Completion
2025-04-30
Completion
2025-07-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04859621 on ClinicalTrials.gov